The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children

Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome

(2013) Dan Knights et al.   GUT

Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment

(2012) Ahmed Abouelnasr et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Guidelines for the management of inflammatory bowel disease in adults

(2011) C. Mowat et al.   GUT

Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review

(2010) Abderrahim Oussalah et al.   CURRENT DRUG TARGETS

Severe Pediatric Ulcerative Colitis: A Prospective Multicenter Study of Outcomes and Predictors of Response

(2010) Dan Turner et al.   GASTROENTEROLOGY

Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?

(2008) William J. Sandborn   GASTROENTEROLOGY

Use of sirolimus (rapamycin) to treat refractory Crohn's disease

(2008) D C O Massey et al.   GUT

Anti tumour necrosis-α therapy increases the number of FOXP3+regulatory T cells in children affected by Crohn’s disease

(2008) Ida Ricciardelli et al.   IMMUNOLOGY

Use of Sirolimus in IPEX and IPEX-Like Children

(2008) Pierre L. Yong et al.   JOURNAL OF CLINICAL IMMUNOLOGY